hiPSC Disease Modeling

Building on the recent advances in working with human induced pluripotent stem cell systems, we have established a versatile portfolio of services for generation of hiPSC disease models.

Sources of hiPSC-derived disease models

Biopsy material (e.g. skin) from clinically diagnosed individuals for generation of hiPSCs and derived cell types

  • Benefit from genetic backgrounds of individual patients

  • Identify and validate disease-causing targets and mechanisms

 

Genome editing (CRISPR/Cas9) in established hiPSC lines to generate synthetic human disease models

  • Study defined disease-causing mutations or alleles

  • Ensure enhanced comparability of observed phenotypes through isogenic background of cellular models

Phenotypic analyses of hiPSC-derived disease models

  • ICC workflows for single cell analysis of synaptic connectivity

  • HCA routines to monitor neuronal development (e.g. neurite outgrowth)

  • Electrophysiological and live cell imaging (e.g. Ca2+-sensitive dyes) recordings to evaluate parameters of neuronal activity

  • RT-qPCR panels (QuantStudio™ 12K Flex) to determine model-specific gene expression signatures

hiPSC | NMI TT Pharmaservices

References

Grunwald, Lena-Marie, et al. "Comparative characterization of human-induced pluripotent stem cells (hiPSC) derived from patients with schizophrenia and autism." Translational psychiatry 9.1 (2019): 179.

Back to top